Natco Pharma receives USFDA nod to market renal disease drug

Aug 16, 2017 08:34 IST

Natco Pharma on 14 August 2017 announced that it has received approval from the US Food and Drug Administration (USFDA) to market Lanthanum Carbonate chewable tablets in various strengths.

The tablets are used in treatment of patients with End Stage Renal Disease (ESRD).

Natco’s Lanthanum Carbonate tablets are indicated to reduce serum phosphate in patients with end stage renal disease.

CA eBook

About Lanthanum Carbonate

Lanthanum carbonate is the salt formed by lanthanum (III) cations and carbonate anions.

It is an ore of lanthanum metal, along with monazite.

It is used in medicine as a phosphate binder. It is prescribed for the treatment of hyperphosphatemia, primarily in patients with chronic kidney disease.

About Natco Pharma

Natco Pharma Limited was incorporated in Hyderabad in the year 1981.

At present, the company has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.

The company is well recognized for its innovation in Pharmaceutical R&D.

Is this article important for exams ? Yes2 People Agreed

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK